Drug Patent Watch

JUNE 3, 2021

Want insights into the biggest revenue-changing events? ? Get Your Certificate Today By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay….

Biosimilars 72

Biosimilars Drugs Marketing 72

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. This event is part of The Drug Channels 2024 Video Webinar Series.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

The Pharma Data

MAY 15, 2023

Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced a multi-year partnership with Just – Evotec Biologics, the Seattle-based subsidiary of Evotec SE.

Biosimilars 40

Biosimilars Production Government Clinical Trials 40

Drug Channels

JULY 11, 2022

Delivered as a Hybrid Event. This important event convenes key stakeholders including manufacturers, specialty pharmacies, hub providers and more for unrivaled collaboration to leverage innovation and optimize access. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Compliance 98

The Pharma Data

MAY 2, 2021

With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept.

Biosimilars 40

Biosimilars Clinical Development Production Government 40

Drug Channels

NOVEMBER 15, 2021

ET This page describes the event and explains how to purchase a registration. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Anyone who registered for the entire series should have received an email with a link to access the December event. Broadcast live on December 17, 2021. to 1:30 p.m.

Specialty Pharmacies 72

Specialty Pharmacies Biosimilars Drugs Pharmacy 72

Drug Channels

OCTOBER 7, 2024

What can be learned from the economic landscape of biosimilars and specialty therapeutics? To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net). What are the latest developments in copay maximizer and accumulator programs? And much more ! All rights reserved.

Pharmacy 97

Pharmacy Biosimilars Compliance Marketing 97

Drug Channels

NOVEMBER 8, 2021

Delivered as a Hybrid Event In-Person: December 13-14, 2021, Hilton Philadelphia at Penn’s Landing, Philadelphia, PA Virtual: December 16-17, 2021 [link]. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Biosimilars Marketing 75

Drug Channels

OCTOBER 17, 2022

To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). Don’t miss the chance to unite with colleagues and master the complexities of pharmacy and distribution models to accelerate patient access! Drug Channels, or any of its employees. Copyright © 2006-2022 Pembroke Consulting, Inc.

Biosimilars 75

Biosimilars Pharmacy Therapies Production 75

Drug Channels

JUNE 5, 2023

thINc’s Specialty Networks and Patient Support Services Summit In-Person Event | August 29-30, 2023 Lowes Philadelphia, Philadelphia, PA www.thinc360.com/specialty com/specialty Early rates are in effect. Use promo code DC5123 to save an additional $100 off the early rates. Register Today!

Specialty Pharmacies 74

Specialty Pharmacies Pharmacy Biosimilars Compliance 74

Drug Channels

MAY 29, 2024

Click here to learn more and reserve your spot at the June 21 event. Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Biosimilars 52

Biosimilars Drugs Marketing 52

FDA Law Blog: Biosimilars

FEBRUARY 26, 2025

The answer to that is still no, the current state of world and governmental events notwithstanding. Finally, effective compliance and quality communication is not a one-off event. For one thing, the possible answers to our rhetorical questions above are not final yet and will take years to sort out.

Compliance 66

Compliance Regulations FDA Government 66

Drug Channels

OCTOBER 23, 2023

Informa Connect’s Trade and Channel Strategies Hybrid Event | December 11-13, 2023 DoubleTree By Hilton | Philadelphia, PA Exclusive Offer–Be sure to use your exclusive promo code 23DC10 to save 10% off* of your registration. Why should you attend this pivotal event? Trade and Channel Strategies is back and we have a lot to talk about!

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Drug Channels

JUNE 26, 2023

To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). View the agenda for Health Systems & Pharma Partnering 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/health-systems-partnering for further details and to register.

Biosimilars 75

Biosimilars Pharmacy Science Therapies 75

The Pharma Data

JUNE 2, 2022

BYOOVIZ™ is the first FDA approved ophthalmology biosimilar BYOOVIZ, priced 40% lower than LUCENTIS®, provides an equally effective and more affordable treatment option to patients suffering from retinal disorders BYOOVIZ will be commercially available through major distributors across the U.S. on July 1, 2022. Biogen Inc.

Biosimilars 52

Biosimilars FDA Approval Treatment Therapies 52

Drug Channels

JUNE 25, 2024

Attendance will be limited, so click here to request an invite for our March 2025 event. Happy 248th birthday, America! Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

Biosimilars 40

Biosimilars Drugs Pharmacy 40

Drug Channels

OCTOBER 15, 2023

To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Biosimilars 74

Biosimilars Drugs Marketing 74

FDA Law Blog: Biosimilars

APRIL 13, 2025

no comparator arm), FOENIX-CCA2 was not capable of establishing improvement on time-to-event efficacy endpoints such as PFS or OS and, without an appropriate comparator, it is not possible to determine if the observed effect is attributable to LYTGOBI or to other factor(s), such as the natural history of the disease. The problem?

Drugs 52

Drugs FDA Trials Treatment 52

FDA Law Blog: Biosimilars

APRIL 7, 2025

You can access the conference brochure and sign up for the event here. FDA Law Blog is a conference media partner. As such, we can offer our readers a special 10% discount. The discount code is: D10-999-FDA25. We look forward to seeing you at the conference!

Science 59

Science Government FDA Pharmaceuticals 59

FDA Law Blog: Biosimilars

FEBRUARY 27, 2025

The conference is billed as the premier event to provide folks with a roadmap to navigate the difficult terrain of FDA regulatory law. You can access the conference brochure and sign up for the event here. And it is exactly that! As such, we can offer our readers a special 10% discount. The discount code is: D10-999-FDA25.

FDA 59

FDA Clinical Trials Regulations Production 59

FDA Law Blog: Drug Discovery

APRIL 21, 2025

FDAs failure to respond to a substantive question in two weeks time is hardly cause for concern, the proximity to the RIFs notwithstanding.Exercising a keen eye to discern which actions or inactions are actually being caused by the recent events may aid us in being more effective at combating them.

52

52

The Pharma Data

NOVEMBER 10, 2020

The event was held in one Chinese session and one English session, with more than 700 investors and analysts watched the webcast and communicated with management team about R&D and other business updates through Q&A.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

FDA Law Blog: Biosimilars

MARCH 7, 2024

What started as a day has — due to its popularity and the persistent efforts of patients and industry — evolved into a week-long event. And my support and pride continue since we now see a host of programs and events the last week of February playing out around the world.

Disease 69

Disease Government FDA Drugs 69

The Pharma Data

DECEMBER 28, 2020

billion, three biosimilar products in development targeting products with a market size of approximately $13.0 Amphastar plans to launch this Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months. Pipeline Information.

FDA 52

FDA Production Biosimilars FDA Approval 52

Eye on FDA

FEBRUARY 10, 2021

Heightened Role for “Bad Ad Program” – A recent interview with the new Acting Director of OPDP revealed that a primary focus for the office this past year was in relation to the biosimilars market. It was also noted that the “ Bad Ad ” program turned 10 years old this year.

FDA 77

FDA Biosimilars Drugs Treatment 77

FDA Law Blog: Biosimilars

JUNE 12, 2024

FDA does, however, expect to issue a report on OTC hearing aid adverse events to Congress by August 2024. The Agency “may issue technology specific regulations and guidance as new hearing technologies are approved and cleared by FDA.” In all, the GAO Report did not provide much in the way of new information for industry.

FDA 111

FDA Regulations Treatment Licensing 111

FDA Law Blog: Biosimilars

NOVEMBER 13, 2023

Designed for in-house legal and compliance counsel, industry executives, and private practice attorneys working for the OTC drug industry, the event will welcome distinguished industry thought leaders – including from the National Advertising Division and FDA – to share their expertise and strategic insights. Director Deborah L.

Compliance 59

Compliance Drugs FDA 59

The Pharma Data

MAY 18, 2021

Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. You should not place undue reliance on these statements.

Biosimilars 40

Biosimilars Production Government Pharmaceuticals 40

FDA Law Blog: Biosimilars

FEBRUARY 26, 2024

The event is set to take place from March 4-6, 2024, in San Francisco, California. The WWCDA Leadership Retreat and Annual Meeting is a cornerstone event for women in white-collar defense law, offering unparalleled opportunities for learning, networking, and advancing the role of women in the legal profession.

FDA 59

FDA Compliance Government International 59

FDA Law Blog: Biosimilars

JANUARY 11, 2024

This day-long (FREE) seminar is a must-attend event for anyone in the pharmaceutical sector interested in understanding the “ins and outs” of doing business in the Territory, as well as an opportunity to interact with those who already have a keen understanding of doing business in Puerto Rico. HPM is a co-sponsor of the event.

Pharmaceuticals 59

Pharmaceuticals Licensing Licensing Compliance 59

The Pharma Data

MARCH 17, 2021

Merck will host a virtual investor event on Monday, May 3 beginning at 10 a.m. Details will be provided at a date closer to the event merck.com/investor-relations. Organon will register its common stock under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”). EDT and lasting approximately two hours.

Biosimilars 40

Biosimilars Pharmaceuticals Production International 40

The Pharma Data

OCTOBER 27, 2020

Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Laboratories 40

Laboratories Biosimilars Government Pharmaceuticals 40

The Pharma Data

DECEMBER 3, 2021

Zuranolone 50 mg was generally well-tolerated with an overall adverse event profile consistent with data reported earlier and 6.5% of patients discontinuing study drug due to adverse events.

Treatment 52

Treatment Biosimilars Disease Clinical Trials 52

The Pharma Data

MARCH 5, 2021

To sustain access, the Novartis generics and biosimilars division Sandoz became the first company to commit to keeping stable prices for a basket of essential medicines that may help in the treatment of COVID-19 and entered into a partnership with US-based Civica Rx to support stable supply of essential generic hospital medicines.

Vaccine 52

Vaccine Production Biosimilars Hospitals 52

FDA Law Blog: Biosimilars

JANUARY 24, 2024

The conference is billed as the premier event to provide folks with a roadmap to navigate the difficult terrain of FDA regulatory law. You can access the conference brochure and sign up for the event here (or by emailing customerservice@americanconference.com or by calling 1-888-224-2480). FDA Law Blog is a conference media partner.

FDA 59

FDA Regulations Science Drugs 59

FDA Law Blog: Biosimilars

JULY 22, 2024

Claud will be speaking at the conference in a session titled “Crafting Your Safety Blueprint for Adverse Events and Recalls under MoCRA.” s John W.M. You can register for the conference here. FDA Law Blog readers receive a 10% discount off the tuition fee (promo code D10-999-FDA25 ).

Compliance 59

Compliance Production Packaging Government 59

FDA Law Blog: Biosimilars

MARCH 8, 2023

Acknowledgement 3 notifies the submitter that the submission was either successfully loaded into CDRH’s adverse event database or that the submission contained errors, which will be specified in the letter. Acknowledgement 2 indicates that the submission reached CDRH.

Packaging 59

Packaging FDA Production Regulations 59